BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer. 1992;50:859-862. [PMID: 1555884 DOI: 10.1002/ijc.2910500604] [Cited by in Crossref: 212] [Cited by in F6Publishing: 208] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER. p53 Expression in Pituitary Adenomas and Carcinomas: Correlation with Invasiveness and Tumor Growth Fractions. Neurosurgery 1996;38:765-71. [DOI: 10.1227/00006123-199604000-00027] [Cited by in Crossref: 172] [Cited by in F6Publishing: 84] [Article Influence: 6.9] [Reference Citation Analysis]
2 Roth JA, Grammer SF. Gene replacement therapy for non-small cell lung cancer: a review. Hematol Oncol Clin North Am 2004;18:215-29. [PMID: 15005290 DOI: 10.1016/s0889-8588(03)00144-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
3 Lewis DJ, Sesterhenn IA, McCarthy WF, Moul JW. Immunohistochemical expression of P53 tumor suppressor gene protein in adult germ cell testis tumors: clinical correlation in stage I disease. J Urol 1994;152:418-23. [PMID: 8015085 DOI: 10.1016/s0022-5347(17)32753-2] [Cited by in Crossref: 43] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
4 Santini D, Tonini G, Vecchio FM, Borzomati D, Vincenzi B, Valeri S, Antinori A, Castri F, Coppola R, Magistrelli P, Nuzzo G, Picciocchi A. Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma. J Clin Pathol 2005;58:159-65. [PMID: 15677536 DOI: 10.1136/jcp.2004.018887] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
5 Piris MA, Villuendas R, Martinez JC, Sanchez-Beato M, Orradre JL, Mateo MS, Martinez P. p53 expression in non-Hodgkin's lymphomas: a marker of p53 inactivation? Leuk Lymphoma 1995;17:35-42. [PMID: 7773162 DOI: 10.3109/10428199509051701] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
6 Teh M, Sun Lee Y. An immunohistochemical study of p53 protein in the different histological subtypes of gastric carcinoma. Pathology 1994;26:432-4. [DOI: 10.1080/00313029400169142] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
7 Nakai H, Misawa S, Taniwaki M, Horiike S, Takashima T, Seriu T, Nakagawa H, Fujii H, Shimazaki C, Maruo N, Akaogi T, Uike N, Abe T, Kashima K. Prognostic significance of loss of a chromosome 17p and p53 gene mutations in blast crisis of chronic myelogenous leukaemia. Br J Haematol 1994;87:425-7. [DOI: 10.1111/j.1365-2141.1994.tb04938.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
8 Sarbia M, Borchard F, Gabbert HE, Porschen R, Horstmann O, Willers R. P53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994;74:2218-23. [DOI: 10.1002/1097-0142(19941015)74:8<2218::aid-cncr2820740803>3.0.co;2-2] [Cited by in Crossref: 94] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
9 Simon D, Goretzki PE, Goreley V, Ebling B, Reishaus E, Lyons J, Haubruck H, R�her HD. Significance of P53 in human thyroid tumors. World J Surg 1994;18:535-40. [DOI: 10.1007/bf00353758] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Wertz IE, Deitch AD, Gumerlock PH, Gandour-edwards R, Chi S, de Vere White RW. Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. Human Pathology 1996;27:573-80. [DOI: 10.1016/s0046-8177(96)90164-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
11 Sakaguchi T, Watanabe A, Sawada H, Yamada Y, Yamashita J, Matsuda M, Nakajima M, Miwa T, Hirao T, Nakano H. Prognostic value of cyclin E and p53 expression in gastric carcinoma. Cancer 1998;82:1238-43. [DOI: 10.1002/(sici)1097-0142(19980401)82:7<1238::aid-cncr5>3.0.co;2-b] [Cited by in Crossref: 43] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
12 Linder S, Parrado C, Falkmer UG, Blåsjö M, Sundelin P, von Rosen A. Prognostic significance of Ki-67 antigen and p53 protein expression in pancreatic duct carcinoma: a study of the monoclonal antibodies MIB-1 and DO-7 in formalin-fixed paraffin-embedded tumour material. Br J Cancer 1997;76:54-9. [PMID: 9218733 DOI: 10.1038/bjc.1997.336] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
13 Takeno S, Noguchi T, Kikuchi R, Sato T, Uchida Y, Yokoyama S. Analysis of the Survival Period in Resectable Stage IV Gastric Cancer. Ann Surg Oncol 2001;8:215-21. [DOI: 10.1007/s10434-001-0215-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
14 Allgayer H, Heiss MM, Schildberg FW. Prognostic factors in gastric cancer: PROGNOSTIC FACTORS IN GASTRIC CANCER. Br J Surg 1997;84:1651-64. [DOI: 10.1046/j.1365-2168.1997.00619.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Roth AD. Curative treatment of gastric cancer: towards a multidisciplinary approach? Crit Rev Oncol Hematol. 2003;46:59-100. [PMID: 12672518 DOI: 10.1016/S1040-8428(02)00160-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
16 Takeno S, Noguchi T, Kikuchi R, Sato T, Uchida Y, Yokoyama S. Analysis of early (pT1) gastric cancer with submucosal invasion: surgical management and possibility to schedule less invasive surgery. Ann Surg Oncol. 2001;8:605-610. [PMID: 11508623 DOI: 10.1007/s10434-001-0605-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
17 Siewert J, Fink U, Sendler A, Becker K, Böttcher K, Feldmann H, Höfler H, Mueller J, Molls M, Nekarda H, Roder J, Stein H. Gastric cancer. Current Problems in Surgery 1997;34:835-939. [DOI: 10.1016/s0011-3840(97)80006-8] [Cited by in Crossref: 37] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
18 Maeda K, Kang S, Onoda N, Ogawa M, Kato Y, Sawada T, Chung KH. Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma. Cancer 1999;86:566-71. [DOI: 10.1002/(sici)1097-0142(19990815)86:4<566::aid-cncr4>3.0.co;2-1] [Cited by in Crossref: 54] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
19 Dalquen P, Sauter G, Torhorst J, Schultheiss E, Jordan P, Lehmann S, Solèr M, Stulz P, Mihatsch MJ, Gudat F. NUCLEAR p53 OVEREXPRESSION IS AN INDEPENDENT PROGNOSTIC PARAMETER IN NODE-NEGATIVE NON-SMALL CELL LUNG CARCINOMA. J Pathol 1996;178:53-8. [DOI: 10.1002/(sici)1096-9896(199601)178:1<53::aid-path415>3.0.co;2-t] [Cited by in Crossref: 32] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
20 Starzynska T, Markiewski M, Domagala W, Marlicz K, Mietkiewski J, Roberts SA, Stern PL. The clinical significance of p53 accumulation in gastric carcinoma. Cancer 1996;77:2005-12. [DOI: 10.1002/(sici)1097-0142(19960515)77:10<2005::aid-cncr7>3.0.co;2-p] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
21 Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F, Bevilacqua G. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 1995;71:1003-7. [PMID: 7734290 DOI: 10.1038/bjc.1995.193] [Cited by in Crossref: 130] [Cited by in F6Publishing: 108] [Article Influence: 5.0] [Reference Citation Analysis]
22 Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A. TP53 and gastric carcinoma: a review. Hum Mutat. 2003;21:258-270. [PMID: 12619111 DOI: 10.1002/humu.10180] [Cited by in Crossref: 160] [Cited by in F6Publishing: 129] [Article Influence: 8.9] [Reference Citation Analysis]
23 Norberg T, Jansson T, Sjoügren S, Mårtensson C, Andréasson I, Fjaüllskog M, Lindman H, Nordgren H, Lindgren A, Holmberg L, Bergh J. Overview on Human Breast Cancer with Focus on Prognostic and Predictive Factors with Special Attention on the Tumour Suppressor Gene P53. Acta Oncologica 2009;35:96-102. [DOI: 10.3109/02841869609083980] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
24 Maeda K, Kang SM, Onoda N, Ogawa M, Kato Y, Sawada T, Chung KH. Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma. Cancer. 1999;86:566-571. [PMID: 10440683 DOI: 10.1002/(SICI)1097-0142(19990815)86:4%3C566::AID-CNCR4%3E3.0.CO;2-1] [Reference Citation Analysis]
25 Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER. p53 Expression in Pituitary Adenomas and Carcinomas: Correlation with Invasiveness and Tumor Growth Fractions: . Neurosurgery. [DOI: 10.1097/00006123-199604000-00027] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
26 Blok P, Craanen ME, Dekker W, Offerhaus GJ, Tytgat GN. No evidence for functional inactivation of wild-type p53 protein by MDM2 overexpression in gastric carcinogenesis. J Pathol. 1998;186:36-40. [PMID: 9875138 DOI: 10.1002/(SICI)1096-9896(199809)186:1%3C36::AID-PATH150%3E3.0.CO;2-R] [Reference Citation Analysis]
27 Herring JA, Shivangi U, Hall CC, Mihas AA, Lynch C, Vijay-Munshi N, Hall TJ. Multiple synchronous primaries of the gastrointestinal tract: a molecular case report. Cancer Lett. 1996;110:1-9. [PMID: 9018074 DOI: 10.1016/s0304-3835(96)04447-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
28 Inoue M, Okayama A, Fujita M, Enomoto T, Sakata M, Tanizawa O, Ueshima H. Clinicopathological characteristics of p53 overexpression in endometrial cancers. Int J Cancer 1994;58:14-9. [PMID: 8014010 DOI: 10.1002/ijc.2910580104] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 1.8] [Reference Citation Analysis]
29 Tan S, Derrick E, Mckee PH, Hobbs C, Ridley M, Neill S. Altered p53 expression and epidermal cell proliferation is seen in vulval lichen sclerosus. J Cutan Pathol 1994;21:316-23. [DOI: 10.1111/j.1600-0560.1994.tb00706.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
30 Nio Y, Sato Y, Song M-, Sumi S-, Minari Y, Yano S, Tamura K. Ki-ras point mutation in codon 12 and expression ofp53 in mucin-producing tumor of the pancreas. J Hep Bil Pancr Surg 1997;4:83-90. [DOI: 10.1007/bf01211347] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
31 Tang H, Hokita S, Che X, Baba M, Aridome K, Kijima F, Tanabe G, Takao S, Aikou T. Comparison of p53 expression in proximal and distal gastric cancer: Histopathologic correlation and prognostic significance. Annals of Surgical Oncology 1997;4:470-4. [DOI: 10.1007/bf02303670] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Lipponen P, Ji H, Aaltomaa S, Syrjänen S, Syrjänen K. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 1993;55:51-6. [PMID: 8344753 DOI: 10.1002/ijc.2910550110] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 2.2] [Reference Citation Analysis]
33 Lee WA, Kim WH, Kim Y, Yang H, Kim J, Kleinman HK. Overexpression of the 67 kD Laminin Receptor Correlates with the Progression of Gastric Carcinoma. Pathology - Research and Practice 1996;192:1195-201. [DOI: 10.1016/s0344-0338(96)80150-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
34 Mcculloch PG, Ochiai A, Hirohashi S, O'dowd GM, Nash JRG, Sasako M. Comparison of the molecular genetics ofc-erb-B2 and p53 expression in stomach cancer in Britain and Japan. Cancer 1995;75:920-5. [DOI: 10.1002/1097-0142(19950215)75:4<920::aid-cncr2820750405>3.0.co;2-e] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
35 Joypaul BV, Hopwood D, Newman EL, Qureshi S, Grant A, Ogston SA, Lane DP, Cuschieri A. The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 1994;69:943-6. [PMID: 8180028 DOI: 10.1038/bjc.1994.182] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 2.4] [Reference Citation Analysis]
36 McCulloch P, Taggart T, Ochiai A, O’Dowd G, Nash J, Sasako M. c-erbB2 and p53 expression are not associated with stage progression of gastric cancer in Britain or Japan. Eur J Surg Oncol. 1997;23:304-309. [PMID: 9315057 DOI: 10.1016/s0748-7983(97)90669-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
37 Hashimoto N, Tachibana M, Dhar DK, Yoshimura H, Nagasue N. Expression of p53 and RB proteins in squamous cell carcinoma of the esophagus: their relationship with clinicopathologic characteristics. Ann Surg Oncol 1999;6:489-94. [PMID: 10458688 DOI: 10.1007/s10434-999-0489-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
38 Nemunaitis J, Swisher S, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence D, Kemp B, Fossella F, Glisson B, Hong W, Khuri F, Kurie J, Lee J, Lee J, Nguyen D, Nesbitt J, Perez-soler R, Pisters KW, Putnam J, Richli W, Shin D, Walsh G, Merritt J, Roth J. Adenovirus-Mediated p53 Gene Transfer in Sequence With Cisplatin to Tumors of Patients With Non–Small-Cell Lung Cancer. JCO 2000;18:609-609. [DOI: 10.1200/jco.2000.18.3.609] [Cited by in Crossref: 237] [Cited by in F6Publishing: 31] [Article Influence: 11.3] [Reference Citation Analysis]
39 Grewal H, Guillem JG, Klimstra DS, Cohen AM. p53 Nuclear overexpression may not be an independent prognostic marker in early colorectal cancer. Diseases of the Colon & Rectum 1995;38:1176-81. [DOI: 10.1007/bf02048333] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
40 Espinoza LA, Tone LG, Neto JB, Costa RS, Wang QJ, Ballejo G. Enhanced TGFalpha-EGFR expression and P53 gene alterations contributes to gastric tumors aggressiveness. Cancer Lett. 2004;212:33-41. [PMID: 15246559 DOI: 10.1016/j.canlet.2004.03.037] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
41 Pich A, Chiarle R, Chiusa L, Motta M, Palestro G. p53 Overexpression and Thymoma Prognosis. In: Marx A, Müller-hermelink HK, editors. Epithelial Tumors of the Thymus. Boston: Springer US; 1997. pp. 47-54. [DOI: 10.1007/978-1-4899-0033-3_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
42 Fléjou JF, Muzeau F, Potet F, Lepelletier F, Fékété F, Hénin D. Overexpression of the p53 tumor suppressor gene product in esophageal and gastric carcinomas. Pathol Res Pract. 1994;190:1141-1148. [PMID: 7540752 DOI: 10.1016/s0344-0338(11)80440-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
43 Rocha FTR, Lourenço LG, Jucá MJ, Leal AT, Paz AMDCD. Expressão da proteína P53 no adenocarcinoma gástrico: correlação clínica, anatomopatológica e significância prognostica. Rev Col Bras Cir 2004;31:186-93. [DOI: 10.1590/s0100-69912004000300008] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
44 Lee HK, Lee HS, Yang HK, Kim WH, Lee KU, Choe KJ, Kim JP. Prognostic significance of Bcl-2 and p53 expression in gastric cancer. Int J Colorectal Dis. 2003;18:518-525. [PMID: 12811476 DOI: 10.1007/s00384-003-0491-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
45 Hamada M, Fujiwara T, Hizuta A, Gochi A, Naomoto Y, Takakura N, Takahashi K, Roth JA, Tanaka N, Orita K. The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J Cancer Res Clin Oncol. 1996;122:360-365. [PMID: 8642047 DOI: 10.1007/bf01220804] [Cited by in Crossref: 78] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
46 Seregni E, Ferrari L, Martinetti A, Bombardieri E. Diagnostic and prognostic tumor markers in the gastrointestinal tract. Semin Surg Oncol 2001;20:147-66. [PMID: 11398208 DOI: 10.1002/ssu.1028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
47 Lee WJ, Shun CT, Hong RL, Wu MS, Chang KJ, Chen KM. Overexpression of p53 predicts shorter survival in diffuse type gastric cancer. Br J Surg. 1998;85:1138-1142. [PMID: 9718015 DOI: 10.1046/j.1365-2168.1998.00712.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis]
48 Kolodziejczyk P, Yao T, Oya M, Nakamura S, Utsunomiya T, Ishikawa T, Tsuneyoshi M. Long-term follow-up study of patients with gastric adenomas with malignant transformation. An immunohistochemical and histochemical analysis. Cancer. 1994;74:2896-2907. [PMID: 7954254 DOI: 10.1002/1097-0142(19941201)74:11%3C2896::AID-CNCR2820741103%3E3.0.CO;2-P] [Reference Citation Analysis]
49 Roa I, Araya JC, Shiraishi T, Yatani R, Wistuba I, Villaseca M, Aretxabala XD. DNA content in gallbladder carcinoma: a flow cytometric study of 96 cases. Histopathology 1993;23:459-64. [DOI: 10.1111/j.1365-2559.1993.tb00495.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
50 Sauter ER, Keller SM, Erner SM. p53 correlates with improved survival in patients with esophageal adenocarcinoma. J Surg Oncol 1995;58:269-73. [PMID: 7723372 DOI: 10.1002/jso.2930580414] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis]
51 Roth JA, Nemunaitis J, Ji L, Ramesh R. Tumor Suppressor Gene Therapy. In: Roth JA, editor. Gene-Based Therapies for Cancer. New York: Springer; 2010. pp. 63-78. [DOI: 10.1007/978-1-4419-6102-0_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
52 Chan AO, Luk JM, Hui WM, Lam SK. Molecular biology of gastric carcinoma: from laboratory to bedside. J Gastroenterol Hepatol. 1999;14:1150-1160. [PMID: 10634150 DOI: 10.1046/j.1440-1746.1999.02000.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 2.0] [Reference Citation Analysis]
53 Stemmermann G, Heffelfinger SC, Noffsinger A, Hui YZ, Miller MA, Fenoglio-Preiser CM. The molecular biology of esophageal and gastric cancer and their precursors: oncogenes, tumor suppressor genes, and growth factors. Hum Pathol. 1994;25:968-981. [PMID: 7927320 DOI: 10.1016/0046-8177(94)90056-6] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 3.0] [Reference Citation Analysis]
54 Osawa S, Shimada Y, Sekine S, Okumura T, Nagata T, Fukuoka J, Tsukada K. MicroRNA profiling of gastric cancer patients from formalin-fixed paraffin-embedded samples. Oncol Lett 2011;2:613-9. [PMID: 22848236 DOI: 10.3892/ol.2011.313] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
55 Steele RJ, Thompson AM, Hall PA, Lane DP. The p53 tumour suppressor gene. Br J Surg. 1998;85:1460-1467. [PMID: 9823903 DOI: 10.1046/j.1365-2168.1998.00910.x] [Cited by in Crossref: 119] [Cited by in F6Publishing: 107] [Article Influence: 5.2] [Reference Citation Analysis]
56 Sasaki I, Yao T, Nawata H, Tsuneyoshi M. Minute gastric carcinoma of differentiated type with special reference to the significance of intestinal metaplasia, proliferative zone, and p53 protein during tumor development. Cancer 1999;85:1719-29. [DOI: 10.1002/(sici)1097-0142(19990415)85:8<1719::aid-cncr11>3.0.co;2-v] [Cited by in Crossref: 27] [Article Influence: 1.2] [Reference Citation Analysis]
57 Mansoor A, Mckee PH, Simpson JA, Mcguire B, Hobbs C. Prognostic Significance of Ki-67 and p53 Immunoreactivity in Cutaneous Squamous Cell Carcinomas: . The American Journal of Dermatopathology 1996;18:351-7. [DOI: 10.1097/00000372-199608000-00004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
58 Yao T, Utsunomiya T, Oya M, Nishiyama K, Tsuneyoshi M. Extremely well-differentiated adenocarcinoma of the stomach: clinicopathological and immunohistochemical features. World J Gastroenterol. 2006;12:2510-2516. [PMID: 16688795 DOI: 10.3748/wjg.v12.i16.2510] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
59 Victorzon M, Nordling S, Haglund C, Lundin J, Roberts P. Expression of p53 protein as a prognostic factor in patients With gastric cancer. European Journal of Cancer 1996;32:215-20. [DOI: 10.1016/0959-8049(95)00547-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
60 Kozuki T, Yao T, Nakamura S, Matsumoto T, Tsuneyoshi M. Differences in p53 and cadherin-catenin complex expression between histological subtypes in diffusely infiltrating gastric carcinoma. Histopathology. 2002;41:56-64. [PMID: 12121238 DOI: 10.1046/j.1365-2559.2002.01407.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
61 Gluckman JL, Stambrook PJ, Pavelic ZP. Prognostic significance of p53 protein accumulation in early stage T1 oral cavity cancer. European Journal of Cancer Part B: Oral Oncology 1994;30:281. [DOI: 10.1016/0964-1955(94)90011-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
62 Gleeson CM, Sloan JM, McManus DT, Maxwell P, Arthur K, McGuigan JA, Ritchie AJ, Russell SE. Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia. Br J Cancer. 1998;77:277-286. [PMID: 9460999 DOI: 10.1038/bjc.1998.44] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 2.6] [Reference Citation Analysis]
63 Aarnio M, Salovaara R, Aaltonen LA, Mecklin JP, Järvinen HJ. Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. Int J Cancer 1997;74:551-5. [PMID: 9355980 DOI: 10.1002/(sici)1097-0215(19971021)74:5<551::aid-ijc13>3.0.co;2-9] [Cited by in Crossref: 111] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
64 Gomyo Y, Ikeda M, Osaki M, Tatebe S, Tsujitani S, Ikeguchi M, Kaibara N, Ito H. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 1997;79:2067-72. [DOI: 10.1002/(sici)1097-0142(19970601)79:11<2067::aid-cncr3>3.0.co;2-m] [Cited by in Crossref: 67] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
65 Fulci G, Ishii N, Van Meir EG. p53 and brain tumors: from gene mutations to gene therapy. Brain Pathol 1998;8:599-613. [PMID: 9804370 DOI: 10.1111/j.1750-3639.1998.tb00187.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 2.1] [Reference Citation Analysis]
66 Lee EU, Cibull ML, O'Daniel-Pierce E, Strodel WE, Jennings CD. Expression of p53 protein in pancreatic adenocarcinoma. Relationship to cigaret smoking. Int J Pancreatol 1995;17:237-42. [PMID: 7642971 DOI: 10.1007/BF02785820] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
67 Gallo O, Franchi A, Bianchi S, Boddi V, Giannelli E, Alajmo E. p53 oncoprotein expression in parotid gland carcinoma is associated with clinical outcome. Cancer 1995;75:2037-44. [DOI: 10.1002/1097-0142(19950415)75:8<2037::aid-cncr2820750802>3.0.co;2-v] [Cited by in Crossref: 63] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
68 Sendler A, Dittler HJ, Feussner H, Nekarda H, Bollschweiler E, Fink U, Helmberger H, H�fler H, Siewert JR. Preoperative staging of gastric cancer as precondition for multimodal treatment. World J Surg 1995;19:501-8. [DOI: 10.1007/bf00294710] [Cited by in Crossref: 36] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
69 Bártek J, Vojtĕsek B, Lane DP. Diversity of human p53 mutants revealed by complex formation to SV40 T antigen. Eur J Cancer 1992;29A:101-7. [PMID: 1332735 DOI: 10.1016/0959-8049(93)90584-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis]
70 Mulder JW, Baas IO, Polak MM, Goodman SN, Offerhaus GJ. Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer 1995;71:1257-62. [PMID: 7779721 DOI: 10.1038/bjc.1995.243] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 1.7] [Reference Citation Analysis]
71 Safatle-ribeiro AV, Ribeiro U, Reynolds JC, Gama-rodrigues JJ, Iriya K, Kim R, Bakker A, Swalsky PA, Pinotti HW, Finkelstein SD. Morphologic, histologic, and molecular similarities between adenocarcinomas arising in the gastric stump and the intact stomach. Cancer 1996;78:2288-99. [DOI: 10.1002/(sici)1097-0142(19961201)78:11<2288::aid-cncr4>3.0.co;2-j] [Cited by in Crossref: 15] [Article Influence: 0.6] [Reference Citation Analysis]
72 Hamelin R, Zucman J, Melot T, Delatre O, Thomas G. p53 mutations in human tumors with chimericEWS/FLI/1 genes. Int J Cancer 1994;57:336-40. [DOI: 10.1002/ijc.2910570308] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 1.3] [Reference Citation Analysis]
73 Roth JA. Adenovirus p53 gene therapy. Expert Opin Biol Ther. 2006;6:55-61. [PMID: 16370914 DOI: 10.1517/14712598.6.1.55] [Cited by in Crossref: 90] [Cited by in F6Publishing: 76] [Article Influence: 6.0] [Reference Citation Analysis]
74 D'Andrea E, Baffa R, Menin C, Montagna M, Rugge M, Chieco-Bianchi L. TP53 gene mutations in gastric carcinoma detected by polymerase chain reaction/single-strand conformation polymorphism analysis of archival material. J Cancer Res Clin Oncol 1995;121:79-83. [PMID: 7883779 DOI: 10.1007/BF01202217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
75 Kubicka S, Claas C, Staab S, Kühnel F, Zender L, Trautwein C, Wagner S, Rudolph KL, Manns M. p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis. Dig Dis Sci. 2002;47:114-121. [PMID: 11837710 DOI: 10.1023/a:1013275706401] [Cited by in Crossref: 41] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
76 Wright PA, Williams GT. Molecular biology and gastric carcinoma. Gut. 1993;34:145-147. [PMID: 8432461 DOI: 10.1136/gut.34.2.145] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 1.5] [Reference Citation Analysis]
77 Awwad S, Jaros E, Somes J, Lunec J. P53 overexpression in head and neck carcinoma and radiotherapy results. International Journal of Radiation Oncology*Biology*Physics 1996;34:323-32. [DOI: 10.1016/0360-3016(95)02108-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 1.4] [Reference Citation Analysis]
78 Hesketh R. P53. The Oncogene & Tumour Suppressor Gene Factsbook. Elsevier; 1997. pp. 446-63. [DOI: 10.1016/b978-012344548-3/50085-6] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
79 Chen G, Burger MM. p150 overexpression in gastric carcinoma: the association with p53, apoptosis and cell proliferation. Int J Cancer 2004;112:393-8. [PMID: 15382063 DOI: 10.1002/ijc.20443] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
80 Yamamoto S, Tomita Y, Hoshida Y, Takiguchi S, Fujiwara Y, Yasuda T, Yano M, Nakamori S, Sakon M, Monden M. Expression level of valosin-containing protein is strongly associated with progression and prognosis of gastric carcinoma. J Clin Oncol. 2003;21:2537-2544. [PMID: 12829673 DOI: 10.1200/JCO.2003.12.102] [Cited by in Crossref: 69] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
81 Ishikawa H, Mitsuhashi N, Sakurai H, Maebayashi K, Niibe H. The effects of p53 status and human papillomavirus infection on the clinical outcome of patients with Stage IIIB cervical carcinoma treated with radiation therapy alone. Cancer 2001;91:80-9. [DOI: 10.1002/1097-0142(20010101)91:1<80::aid-cncr11>3.0.co;2-e] [Cited by in Crossref: 35] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
82 Haines DS. The mdm2 Proto-Oncogene. Leukemia & Lymphoma 2009;26:227-38. [DOI: 10.3109/10428199709051772] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
83 Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999;229:303-308. [PMID: 10077040 DOI: 10.1097/00000658-199903000-00001] [Cited by in Crossref: 179] [Cited by in F6Publishing: 147] [Article Influence: 8.1] [Reference Citation Analysis]
84 Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, Williams KE, Turbett GR, House AK, Iacopetta BJ. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Human Pathology 1996;27:1050-5. [DOI: 10.1016/s0046-8177(96)90282-8] [Cited by in Crossref: 114] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
85 Ayed DB, Khabir A, Abid M, Bayrouti MI, Gargouri A, Sellami-Boudawara T, Mokdad-Gargouri R. Clinicopathological and prognostic significance of p53, Ki-67, and Bcl-2 expression in Tunisian gastric adenocarcinomas. Acta Histochem 2014;116:1244-50. [PMID: 25095748 DOI: 10.1016/j.acthis.2014.07.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
86 Sakaguchi T, Watanabe A, Sawada H, Yamada Y, Tatsumi M, Fujimoto H, Emoto K, Nakano H. Characteristics and clinical outcome of proximal-third gastric cancer. J Am Coll Surg 1998;187:352-7. [PMID: 9783780 DOI: 10.1016/s1072-7515(98)00191-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
87 Hoppe-Seyler F, Butz K. Tumor suppressor genes in molecular medicine. Clin Investig. 1994;72:619-630. [PMID: 7819720 DOI: 10.1007/bf00227456] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
88 Gabbert HE, Müller W, Schneiders A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 1995;76:720-6. [DOI: 10.1002/1097-0142(19950901)76:5<720::aid-cncr2820760503>3.0.co;2-e] [Cited by in Crossref: 73] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
89 Kodama M, Fujioka T, Kodama R, Takahashi K, Kubota T, Murakami K, Nasu M. p53 expression in gastric mucosa with Helicobacter pylori infection. J Gastroenterol Hepatol. 1998;13:215-219. [PMID: 10221826 DOI: 10.1111/j.1440-1746.1998.tb00640.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 0.4] [Reference Citation Analysis]
90 Deveci MS, Deveci G. Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma. Gastric Cancer. 2007;10:112-116. [PMID: 17577621 DOI: 10.1007/s10120-007-0418-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
91 Pich A, Chiarle R, Chiusa L, Ponte R, Geuna M, Palestro G. p53 expression and proliferative activity predict survival in non-invasive thymomas. Int J Cancer 1996;69:180-3. [DOI: 10.1002/(sici)1097-0215(19960621)69:3<180::aid-ijc5>3.0.co;2-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
92 Scheiman JM, Cutler AF. Helicobacter pylori and gastric cancer. Am J Med. 1999;106:222-226. [PMID: 10230753 DOI: 10.1016/s0002-9343(98)00393-3] [Cited by in Crossref: 59] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
93 Craanen ME, Blok P, Dekker W, Offerhaus GJ, Tytgat GN. Chronology of p53 protein accumulation in gastric carcinogenesis. Gut 1995;36:848-52. [PMID: 7615272 DOI: 10.1136/gut.36.6.848] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 1.6] [Reference Citation Analysis]
94 Kubba A, Macintyre I. Gastric cancer distal to the cardia—prevention or cure? Surgical Oncology 1997;6:111-24. [DOI: 10.1016/s0960-7404(97)00011-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
95 Nakopoulou L, Janinis J, Giannopoulou I, Lazaris AC, Koureas A, Zacharoulis D. Immunohistochemical expression of p53 protein and proliferating cell nuclear antigen in hepatocellular carcinoma. Pathol Res Pract. 1995;191:1208-1213. [PMID: 8927568 DOI: 10.1016/S0344-0338(11)81128-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Patterson H, Gill S, Fisher C, Law MG, Jayatilake H, Fletcher CD, Thomas M, Grimer R, Gusterson BA, Cooper CS. Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. Br J Cancer 1994;69:1052-8. [PMID: 8198970 DOI: 10.1038/bjc.1994.207] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 1.5] [Reference Citation Analysis]
97 Nakopoulou L, Vourlakou C, Zervas A, Tzonou A, Gakiopoulou H, Dimopoulos MA. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol. 1998;29:146-154. [PMID: 9490274 DOI: 10.1016/s0046-8177(98)90225-8] [Cited by in Crossref: 87] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
98 Sasano H, Date F, Imatani A, Asaki S, Nagura H. Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol. 1993;24:584-589. [PMID: 8099338 DOI: 10.1016/0046-8177(93)90236-a] [Cited by in Crossref: 53] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
99 D’Errico A, Barozzi C, Fiorentino M, Carella R, Di Simone M, Ferruzzi L, Mattioli S, Grigioni WF. Role and new perspectives of transforming growth factor-alpha (TGF-alpha) in adenocarcinoma of the gastro-oesophageal junction. Br J Cancer. 2000;82:865-870. [PMID: 10732760 DOI: 10.1054/bjoc.1999.1013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
100 Chansky H, Robbins JR, Cha S, Raskind WH, Conrad EU, Sandell LJ. Expression of cartilage extracellular matrix and potential regulatory genes in a new human chondrosarcoma cell line. J Orthop Res 1998;16:521-30. [DOI: 10.1002/jor.1100160502] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.3] [Reference Citation Analysis]
101 Sauter ER, Ridge JA, Klein-szanto A, Track B, Cleveland D, Whitley KV, Mohr RM. Overexpression of the p53 gene in primary and metastatic head and neck carcinomas. Laryngoscope 1995;105:653-6. [DOI: 10.1288/00005537-199506000-00018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
102 Lane DP. On the expression of the p53 protein in human cancer. Mol Biol Rep 1994;19:23-9. [PMID: 8170465 DOI: 10.1007/BF00987319] [Cited by in Crossref: 31] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
103 Danks RA, Chopra G, Gonzales MF, Orian JM, Kaye AH. Aberrant p53 Expression Does Not Correlate with the Prognosis in Anaplastic Astrocytoma. Neurosurgery 1995;37:246-54. [DOI: 10.1227/00006123-199508000-00009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
104 Kolodziejczyk P, Yao T, Oya M, Nakamura S, Utsunomiya T, Ishikawa T, Tsuneyoshi M. Long term follow-up study of patients with gastric adenomas with malignant transformation. An immunohistochemical and histochemical analysis. Cancer 1994;74:2896-907. [DOI: 10.1002/1097-0142(19941201)74:11<2896::aid-cncr2820741103>3.0.co;2-p] [Cited by in Crossref: 43] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
105 Isozaki H, Okajima K, Hu X, Fujii K, Sako S. Multiple early gastric carcinomas: Clinicopathologic features and histogenesis. Cancer 1996;78:2078-86. [DOI: 10.1002/(sici)1097-0142(19961115)78:10<2078::aid-cncr7>3.0.co;2-k] [Cited by in Crossref: 20] [Article Influence: 0.8] [Reference Citation Analysis]
106 Kaye P, Radebold K, Isaacs S, Dent D. Expression of p53 and p21waf1/cip1in gastric carcinoma: lack of inter-relationship or correlation with prognosis. European Journal of Surgical Oncology (EJSO) 2000;26:39-43. [DOI: 10.1053/ejso.1999.0738] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
107 Uchino S, Noguchi M, Ochiai A, Saito T, Kobayashi M, Hirohashi S. p53 mutation in gastric cancer: a genetic model for carcinogenesis is common to gastric and colorectal cancer. Int J Cancer 1993;54:759-64. [PMID: 8392033 DOI: 10.1002/ijc.2910540509] [Cited by in Crossref: 142] [Cited by in F6Publishing: 117] [Article Influence: 5.1] [Reference Citation Analysis]
108 Kawamura T, Goseki N, Koike M, Takizawa T, Endo M. Acceleration of proliferative activity of esophageal squamous cell carcinoma with invasion beyond the mucosa: Immunohistochemical analysis of Ki-67 and p53 antigen in relation to histopathologic findings. Cancer 1996;77:843-9. [DOI: 10.1002/(sici)1097-0142(19960301)77:5<843::aid-cncr6>3.0.co;2-f] [Cited by in Crossref: 22] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
109 Kohlberger P, Kainz C, Breitenecker G, Gitsch G, Sliutz G, Kolbl H, Tschachler E, Reinthaller A. Prognostic value of immunohistochemically detected p53 expression in vulvar carcinoma. Cancer 1995;76:1786-9. [DOI: 10.1002/1097-0142(19951115)76:10<1786::aid-cncr2820761016>3.0.co;2-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
110 Oka K, Nakano T, Arai T. p53CM1 expression is not associated with prognosis in uterine cervical carcinoma. Cancer 1993;72:160-4. [DOI: 10.1002/1097-0142(19930701)72:1<160::aid-cncr2820720130>3.0.co;2-c] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
111 Allgayer H, Heiss MM, Schildberg FW. Prognostic factors in gastric cancer. Br J Surg. 1997;84:1651-1664. [PMID: 9448610 DOI: 10.1002/bjs.1800841206] [Cited by in Crossref: 60] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
112 Ribeiro U, Finkelstein SD, Safatle-ribeiro AV, Landreneau RJ, Clarke MR, Bakker A, Swalsky PA, Gooding WE, Posner MC. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 1998;83:7-18. [DOI: 10.1002/(sici)1097-0142(19980701)83:1<7::aid-cncr2>3.0.co;2-r] [Cited by in Crossref: 98] [Article Influence: 4.3] [Reference Citation Analysis]
113 Symmans PJ, Linehan JM, Brito MJ, Filipe MI. p53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7. J Pathol. 1994;173:221-226. [PMID: 7931842 DOI: 10.1002/path.1711730304] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.0] [Reference Citation Analysis]
114 Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ. Gain of function mutations in p53. Nat Genet 1993;4:42-6. [PMID: 8099841 DOI: 10.1038/ng0593-42] [Cited by in Crossref: 565] [Cited by in F6Publishing: 532] [Article Influence: 20.2] [Reference Citation Analysis]
115 Hsieh LL, Hsieh JT, Wang LY, Fang CY, Chang SH, Chen TC. p53 mutations in gastric cancers from Taiwan. Cancer Lett. 1996;100:107-113. [PMID: 8620428 DOI: 10.1016/0304-3835(95)04077-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
116 Marks JR, Davidoff AM, Iglehart JD. p53 in Human Cancer. In: Garrett CT, Sell S, editors. Cellular Cancer Markers. Totowa: Humana Press; 1995. pp. 77-110. [DOI: 10.1007/978-1-4757-2381-6_4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
117 Tsujitani S, Saito H, Wakatsuki T, Ikeguchi M, Shirabe K, Morita M, Kakeji Y, Yano T, Maehara Y. Relationship between expression of apoptosis-related proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer. Surg Today. 2012;42:225-232. [PMID: 22143356 DOI: 10.1007/s00595-011-0062-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
118 Ueyama H, Yao T, Nakashima Y, Hirakawa K, Oshiro Y, Hirahashi M, Iwashita A, Watanabe S. Gastric adenocarcinoma of fundic gland type (chief cell predominant type): proposal for a new entity of gastric adenocarcinoma. Am J Surg Pathol. 2010;34:609-619. [PMID: 20410811 DOI: 10.1097/pas.0b013e3181d94d53] [Cited by in Crossref: 95] [Cited by in F6Publishing: 40] [Article Influence: 8.6] [Reference Citation Analysis]
119 Lane DP. The regulation of p53 function: Steiner Award Lecture. Int J Cancer. 1994;57:623-627. [PMID: 8194867 DOI: 10.1002/ijc.2910570502] [Cited by in Crossref: 103] [Cited by in F6Publishing: 95] [Article Influence: 3.8] [Reference Citation Analysis]
120 Starzynska T, Marsh P, Stern P. p53 Overexpression as a marker of malignancy in gastric biopsies. Surgical Oncology 1993;2:321-4. [DOI: 10.1016/0960-7404(93)90062-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
121 Kobayashi S, Koide Y, Endo M, Isono K, Ochiai T. The p53 gene mutation is of prognostic value in esophageal squamous cell carcinoma patients in unified stages of curability. Am J Surg. 1999;177:497-502. [PMID: 10414702 DOI: 10.1016/s0002-9610(99)00085-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
122 Dy GK, Adjei AA. Novel Targets for Lung Cancer Therapy: Part II. JCO 2002;20:3016-28. [DOI: 10.1200/jco.2002.02.112] [Cited by in Crossref: 53] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
123 Müller W, Borchard F. PROGNOSTIC INFLUENCE OF p53 EXPRESSION IN GASTRIC CANCER. J Pathol 1996;178:255-8. [DOI: 10.1002/(sici)1096-9896(199603)178:3<255::aid-path468>3.0.co;2-v] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
124 Xue J, Yang H, Huang S, Zhou T, Zhang X, Zu G. Comparison of the overall survival of proximal and distal gastric cancer after gastrectomy: a systematic review and meta-analysis. World J Surg Oncol 2021;19:17. [PMID: 33468158 DOI: 10.1186/s12957-021-02126-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Guan XY, Fu SB, Xia JC, Fang Y, Sham JS, Du BD, Zhou H, Lu S, Wang BQ, Lin YZ. Recurrent chromosome changes in 62 primary gastric carcinomas detected by comparative genomic hybridization. Cancer Genet Cytogenet. 2000;123:27-34. [PMID: 11120330 DOI: 10.1016/s0165-4608(00)00306-x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
126 Levesque MA, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis EP. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995;75:1327-38. [DOI: 10.1002/1097-0142(19950315)75:6<1327::aid-cncr2820750615>3.0.co;2-p] [Cited by in Crossref: 82] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
127 R. Blank, M. S. Rudoltz, G. D. Kao, K. Review: The molecular regulation of apoptosis and implications for radiation oncology. International Journal of Radiation Biology 2009;71:455-66. [DOI: 10.1080/095530097143789] [Cited by in Crossref: 48] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
128 Nakamori S, Yashima K, Murakami Y, Ishikawa O, Ohigashi H, Imaoka S, Yaegashi S, Konishi Y, Sekiya T. Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Jpn J Cancer Res 1995;86:174-81. [PMID: 7730141 DOI: 10.1111/j.1349-7006.1995.tb03036.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 2.1] [Reference Citation Analysis]
129 Barnabas N, Shurafa M, Van Dyke DL, Wolman SR, Clark D, Worsham MJ. Significance of p53 mutations in patients with chronic lymphocytic leukemia: A sequential study of 30 patients. Cancer 2001;91:285-93. [DOI: 10.1002/1097-0142(20010115)91:2<285::aid-cncr1000>3.0.co;2-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
130 Ogawa M, Maeda K, Onoda N, Chung YS, Sowa M. Loss of p21WAF1/CIP1 expression correlates with disease progres-sion in gastric carcinoma. Br J Cancer. 1997;75:1617-1620. [PMID: 9184177 DOI: 10.1038/bjc.1997.276] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 1.7] [Reference Citation Analysis]
131 Blanchet A, Bourgmayer A, Kurtz JE, Mellitzer G, Gaiddon C. Isoforms of the p53 Family and Gastric Cancer: A Ménage à Trois for an Unfinished Affair. Cancers (Basel) 2021;13:916. [PMID: 33671606 DOI: 10.3390/cancers13040916] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
132 Tech M, Wee A, Raju GC. An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct/ampullary carcinomas. Cancer 1994;74:1542-5. [DOI: 10.1002/1097-0142(19940901)74:5<1542::aid-cncr2820740508>3.0.co;2-u] [Cited by in Crossref: 52] [Cited by in F6Publishing: 6] [Article Influence: 1.9] [Reference Citation Analysis]
133 Gürel S, Dolar E, Yerci Ö, Samli B, Öztürk H, Nak S, Gülten M, Memik F. Expression of p53 Protein and Prognosis in Gastric Carcinoma. J Int Med Res 1999;27:85-9. [DOI: 10.1177/030006059902700205] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
134 Lleonart ME, Garc�a-foncillas J, S�nchez-prieto R, Mart�n P, Moreno A, Salas C, Cajal SRY. Microsatellite instability and p53 mutations in sporadic right and left colon carcinoma: Different clinical and molecular implications. Cancer 1998;83:889-95. [DOI: 10.1002/(sici)1097-0142(19980901)83:5<889::aid-cncr13>3.0.co;2-r] [Cited by in Crossref: 24] [Article Influence: 1.0] [Reference Citation Analysis]
135 Maehara Y, Emi Y, Tomisaki S, Oshiro T, Kakeji Y, Ichiyoshi Y, Sugimachi K. Age-related characteristics of gastric carcinoma in young and elderly patients. Cancer 1996;77:1774-80. [PMID: 8646673 DOI: 10.1002/(SICI)1097-0142(19960501)77:9<1774::AID-CNCR3>3.0.CO;2-C] [Cited by in Crossref: 45] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
136 Craanen ME, Blok P, Offerhaus GJ, Meijer GA, Dekker W, Kuipers EJ, Meuwissen SG. p21(Waf1/Cip1) expression and the p53/MDM2 feedback loop in gastric carcinogenesis. J Pathol 1999;189:481-6. [PMID: 10629547 DOI: 10.1002/(SICI)1096-9896(199912)189:4<481::AID-PATH482>3.0.CO;2-U] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
137 Mukhopadhyay D, Chatterjee R, Chakraborty RN. Association of p53 expression with cytokinetics and HPV capsid antigen prevalence in oral carcinomas. Cancer Letters 1994;87:99-105. [DOI: 10.1016/0304-3835(94)90415-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
138 Heidenreich A, Schenkman NS, Sesterhenn IA, Mostofi KF, Moul JW, Srivastava S, Engelmann UH. Immunohistochemical and mutational analysis of the p53 tumour suppressor gene and the bcl-2 oncogene in primary testicular germ cell tumours. APMIS 1998;106:90-100. [DOI: 10.1111/j.1699-0463.1998.tb01324.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
139 Sawyers JL. Gastric carcinoma. Current Problems in Surgery 1995;32:101-78. [DOI: 10.1016/s0011-3840(05)80009-7] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
140 Danesi DT, Spanò M, Antonini F, Altavista P, Catalano P, Cordelli E, Pasqualetti P, Santacroce C, Toscano MG, Mecozzi A, Fabiano A. Flow Cytometric and Immunohistochemical Correlations in High Incidence Human Solid Tumors. Tumori 1997;83:689-97. [DOI: 10.1177/030089169708300313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Lim BHG, Soong R, Grieu F, Robbins PD, House AK, Iacopetta BJ. p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma. Int J Cancer 1996;69:200-4. [DOI: 10.1002/(sici)1097-0215(19960621)69:3<200::aid-ijc9>3.0.co;2-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
142 Hamelin R, Laurent-puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, Girodet J, Salmon RJ, Thomas G. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106:42-8. [DOI: 10.1016/s0016-5085(94)94217-x] [Cited by in Crossref: 237] [Cited by in F6Publishing: 56] [Article Influence: 8.8] [Reference Citation Analysis]
143 Nakai H, Misawa S. Chromosome 17 Abnormalities and Inactivation of the P53 Gene in Chronic Myeloid Leukemia and Their Prognostic Significance. Leukemia & Lymphoma 2009;19:213-21. [DOI: 10.3109/10428199509107891] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
144 Lee HS, Lee HK, Kim HS, Yang H, Kim WH. Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 2003;200:39-46. [DOI: 10.1002/path.1288] [Cited by in Crossref: 126] [Cited by in F6Publishing: 120] [Article Influence: 7.0] [Reference Citation Analysis]
145 Tahara E. Molecular mechanism of stomach carcinogenesis. J Cancer Res Clin Oncol. 1993;119:265-272. [PMID: 8440743 DOI: 10.1007/bf01212724] [Cited by in Crossref: 229] [Cited by in F6Publishing: 62] [Article Influence: 8.2] [Reference Citation Analysis]
146 Loriaux PM, Hoffmann A. A protein turnover signaling motif controls the stimulus-sensitivity of stress response pathways. PLoS Comput Biol 2013;9:e1002932. [PMID: 23468615 DOI: 10.1371/journal.pcbi.1002932] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
147 Joypaul BV, Newman EL, Hopwood D, Grant A, Qureshi S, Lane DP, Cuschieri A. Expression of p53 protein in normal, dysplastic, and malignant gastric mucosa: an immunohistochemical study. J Pathol. 1993;170:279-283. [PMID: 8133401 DOI: 10.1002/path.1711700310] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 2.1] [Reference Citation Analysis]
148 Ismail T, Hallissey MT, Fielding JWL. Pathologic prognostic factors for gastrointestinal cancer. World J Surg 1995;19:178-83. [DOI: 10.1007/bf00308623] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
149 Cheng Q, Luo X, Zhang B, Jiang X, Yi B, Wu M. Distal bile duct carcinoma: prognostic factors after curative surgery. A series of 112 cases. Ann Surg Oncol. 2007;14:1212-1219. [PMID: 17176983 DOI: 10.1245/s10434-006-9260-0] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
150 Auvinen A, Isola J, Visakorpi T, Koivula T, Virtanen S, Hakama M. Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer. 1994;70:293-296. [PMID: 8054278 DOI: 10.1038/bjc.1994.295] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 1.7] [Reference Citation Analysis]
151 Mönig SP, Eidt S, Zirbes TK, Stippel D, Baldus SE, Pichlmaier H. p53 expression in gastric cancer: clinicopathological correlation and prognostic significance. Dig Dis Sci 1997;42:2463-7. [PMID: 9440620 DOI: 10.1023/a:1018844008068] [Cited by in Crossref: 21] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
152 Ajani JA, Mansfield PF, Ota DM. Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. World J Surg. 1995;19:216-220. [PMID: 7754626 DOI: 10.1007/bf00308629] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
153 Poremba C, W. Yandell D, Mellin W, W. Schmid K, Reers B, Böcker W, Dockhorn-dworniczak B. Adenocarcinoma of the Cardia in a Young Man: Detection of Somatic p53 Mutation by Immunohistochemistry and Automated Direct Sequencing. Pathology - Research and Practice 1995;191:1004-9. [DOI: 10.1016/s0344-0338(11)80599-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
154 Hardwick RH, Barham CP, Ozua P, Newcomb PV, Savage P, Powell R, Rahamin J, Alderson D. Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis. Eur J Surg Oncol. 1997;23:30-35. [PMID: 9066744 DOI: 10.1016/s0748-7983(97)80139-4] [Cited by in Crossref: 56] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
155 Mcgregor J, Yu C, Dublin E, Levison D, Macdonald D. Aberrant expression of p53 tumour-suppressor protein in non-melanoma skin cancer. Br J Dermatol 1992;127:463-9. [DOI: 10.1111/j.1365-2133.1992.tb14841.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 2.3] [Reference Citation Analysis]
156 Filipe MI, Osborn M, Linehan J, Sanidas E, Brito MJ, Jankowski J. Expression of transforming growth factor alpha, epidermal growth factor receptor and epidermal growth factor in precursor lesions to gastric carcinoma. Br J Cancer 1995;71:30-6. [PMID: 7819044 DOI: 10.1038/bjc.1995.7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 1.4] [Reference Citation Analysis]
157 Würl P, Weigmann F, Meye A, Fittkau M, Rose U, Berger D, Rath FW, Dralle H, Taubert H. Detection of p53 Autoantibodies in Sera of Gastric Cancer Patients and Their Prognostic Relevance. Scandinavian Journal of Gastroenterology 2009;32:1147-51. [DOI: 10.3109/00365529709002995] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
158 O»hanlon D, Kiely M, Macconmara M, Al-azzawi R, Connolly Y, Jeffers M, Keane F. An immunohistochemical study of p21 and p53 expression in primary node-positive breast carcinoma. European Journal of Surgical Oncology (EJSO) 2002;28:103-7. [DOI: 10.1053/ejso.2001.1224] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
159 Kanamoto A, Kato H, Tachimori Y, Watanabe H, Nakanishi Y, Kondo H, Yamaguchi H, Gotoda T, Muro K, Matsumura Y. No prognostic significance of p53 expression in esophageal squamous cell carcinoma. J Surg Oncol 1999;72:94-8. [DOI: 10.1002/(sici)1096-9098(199910)72:2<94::aid-jso10>3.0.co;2-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
160 Mcgregor J, Dublin E, Levison D, Macdonald D, Smith N, Whittaker S. p53 immunoreactivity is uncommon in primary cutaneous lymphoma. Br J Dermatol 1995;132:353-8. [DOI: 10.1111/j.1365-2133.1995.tb08667.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
161 Watanabe R, Tomita Y, Nishiyama T, Tanikawa T, Sato S. Correlation of p53 protein expression in human urothelial transitional cell cancers with malignant potential and patient survival. Int J Urol 1994;1:43-8. [PMID: 7627837 DOI: 10.1111/j.1442-2042.1994.tb00007.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
162 Tamilzhalagan S, Rathinam D, Ganesan K. Amplified 7q21-22 gene MCM7 and its intronic miR-25 suppress COL1A2 associated genes to sustain intestinal gastric cancer features. Mol Carcinog 2017;56:1590-602. [DOI: 10.1002/mc.22614] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
163 Mattioli E, Vogiatzi P, Sun A, Abbadessa G, Angeloni G, D’Ugo D, Trani D, Gaughan JP, Vecchio FM, Cevenini G. Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer. J Cell Physiol. 2007;210:183-191. [PMID: 16998811 DOI: 10.1002/jcp.20833] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
164 Suzuki H, Matsumoto K, Koide A, Tada T, Fujino I, Okuda A, Shigemori C. Correlation of p53 with the clinicopathologic features and prognosis of colorectal adenocarcinoma. Surg Today 1994;24:85-7. [PMID: 8054784 DOI: 10.1007/BF01676893] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
165 Ikeguchi M, Oka S, Saito H, Kondo A, Tsujitani S, Maeta M, Kaibara N. Computerized nuclear morphometry: a new morphologic assessment for advanced gastric adenocarcinoma. Ann Surg 1999;229:55-61. [PMID: 9923800 DOI: 10.1097/00000658-199901000-00007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
166 Pritchard DM, Watson AJ. Apoptosis and gastrointestinal pharmacology. Pharmacol Ther. 1996;72:149-169. [PMID: 8981574 DOI: 10.1016/s0163-7258(96)00102-7] [Cited by in Crossref: 53] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
167 Mcgregor J, Yu C, Dublin E, Barnes D, Levison D, Macdonald D. p53 immunoreactivity in human malignant melanoma and dysplastic naevi. Br J Dermatol 1993;128:606-11. [DOI: 10.1111/j.1365-2133.1993.tb00253.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 2.0] [Reference Citation Analysis]
168 Blok P, Craanen ME, Dekker W, Offerhaus GJA, Tytgat GNJ. No evidence for functional inactivation of wild-type p53 protein by MDM2 overexpression in gastric carcinogenesis. J Pathol 1998;186:36-40. [DOI: 10.1002/(sici)1096-9896(199809)186:1<36::aid-path150>3.0.co;2-r] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
169 Gimenez-conti IB, Labate M, Liu F, Osterndorff E. p53 alterations in chemically induced hamster cheek-pouch lesions. Mol Carcinog 1996;16:197-202. [DOI: 10.1002/(sici)1098-2744(199608)16:4<197::aid-mc3>3.0.co;2-d] [Cited by in Crossref: 29] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
170 Coffin CM, Hamilton MS, Pysher TJ, Bach P, Ashwood E, Schweiger J, Monahan D, Perry D, Rogers BB, Brugnara C, Rutledge J, Weiss R, Ash O, Hill H, Meikle W, Roberts W, Geaghan S. Pediatric laboratory medicine: current challenges and future opportunities. Am J Clin Pathol 2002;117:683-90. [PMID: 12090415 DOI: 10.1309/NYA1-V9KQ-NVF8-MA8M] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
171 Hermanek P, Maruyama K, Sobin LH. Stomach Carcinoma. In: Hermanek P, Gospodarowicz MK, Henson DE, Hutter RVP, Sobin LH, editors. Prognostic Factors in Cancer. Berlin: Springer Berlin Heidelberg; 1995. pp. 47-63. [DOI: 10.1007/978-3-642-79395-0_6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
172 Roth JA, Grammer SF, Swisher SG, Nemunaitis J, Merritt J, Meyn RE. Gene replacement strategies for treating non-small cell lung cancer. Seminars in Radiation Oncology 2000;10:333-42. [DOI: 10.1053/srao.2000.9127] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
173 Mcgregor JM, Farthing A, Crook T, Yu CC, Dublin EA, Levison DA, Macdonald DM. Posttransplant skin cancer: A possible role for p53 gene mutation but not for oncogenic human papillomaviruses. Journal of the American Academy of Dermatology 1994;30:701-6. [DOI: 10.1016/s0190-9622(08)81498-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
174 Saegusa M, Takano Y, Okayasu I. Bcl-2 expression and its association with cell kinetics in human gastric carcinomas and intestinal metaplasia. J Cancer Res Clin Oncol. 1995;121:357-363. [PMID: 7797601 DOI: 10.1007/bf01225688] [Cited by in Crossref: 42] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
175 Oda T, Murakami K, Nishizono A, Kodama M, Nasu M, Fujioka T. Long-term Helicobacter pylori infection in Japanese monkeys induces atrophic gastritis and accumulation of mutations in the p53 tumor suppressor gene. Helicobacter. 2002;7:143-151. [PMID: 12047319 DOI: 10.1046/j.1523-5378.2002.00074.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
176 Kitayama Y, Sugimura H, Tanaka M, Nakamura S, Kino I. Expression of p53 and flow cytometric DNA analysis of isolated neoplastic glands of the stomach: an application of the gland isolation method. Virchows Arch 1995;426:557-62. [PMID: 7655735 DOI: 10.1007/BF00192109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
177 Okusa Y, Ichikura T, Tamakuma S. Immunohistochemical staining for the p53 protein and proliferating cell nuclear antigen in familial clustering of gastric cancer. J Surg Oncol 1996;62:253-7. [DOI: 10.1002/(sici)1096-9098(199608)62:4<253::aid-jso5>3.0.co;2-5] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
178 Wu MS, Shun CT, Sheu JC, Wang HP, Wang JT, Lee WJ, Chen CJ, Wang TH, Lin JT. Overexpression of mutant p53 and c-erbB-2 proteins and mutations of the p15 and p16 genes in human gastric carcinoma: with respect to histological subtypes and stages. J Gastroenterol Hepatol 1998;13:305-10. [PMID: 9570245 DOI: 10.1111/j.1440-1746.1998.01560.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 1.0] [Reference Citation Analysis]
179 Lipponen PK. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 1993;53:365-70. [DOI: 10.1002/ijc.2910530304] [Cited by in Crossref: 182] [Cited by in F6Publishing: 138] [Article Influence: 6.5] [Reference Citation Analysis]
180 Kim N, Cho SI, Lee HS, Park JH, Kim JH, Kim JS, Jung HC, Song IS. The discrepancy between genetic polymorphism of p53 codon 72 and the expression of p53 protein in Helicobacter pylori-associated gastric cancer in Korea. Dig Dis Sci. 2010;55:101-110. [PMID: 19184427 DOI: 10.1007/s10620-008-0688-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
181 Nabeya Y, Loganzo F, Maslak P, Lai L, de Oliveira AR, Schwartz GK, Blundell ML, Altorki NK, Kelsen DP, Albino AP. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer. 1995;64:37-46. [PMID: 7665247 DOI: 10.1002/ijc.2910640109] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 2.4] [Reference Citation Analysis]
182 Misra S, Chaturvedi A, Goel MM, Mehrotra R, Sharma ID, Srivastava AN, Misra NC. Overexpression of p53 protein in gallbladder carcinoma in North India. Eur J Surg Oncol. 2000;26:164-167. [PMID: 10744937 DOI: 10.1053/ejso.1999.0763] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
183 Wang X, MacLennan GT, Lopez-Beltran A, Cheng L. Small cell carcinoma of the urinary bladder--histogenesis, genetics, diagnosis, biomarkers, treatment, and prognosis. Appl Immunohistochem Mol Morphol 2007;15:8-18. [PMID: 17536302 DOI: 10.1097/01.pai.0000213106.12731.d7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
184 Nio Y, Dong M, Iguchi C, Yamasawa K, Toga T, Itakura M, Tamura K. Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: effects on clinical outcome and efficacy of adjuvant chemotherapy. J Surg Oncol 2001;76:188-96. [PMID: 11276023 DOI: 10.1002/jso.1033] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
185 Powell AG, Hughes DL, Wheat JR, Lewis WG. The 100 most influential manuscripts in gastric cancer: A bibliometric analysis. International Journal of Surgery 2016;28:83-90. [DOI: 10.1016/j.ijsu.2016.02.028] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 6.6] [Reference Citation Analysis]
186 Collier JD, Carpenter M, Burt AD, Bassendine MF. Expression of mutant p53 protein in hepatocellular carcinoma. Gut. 1994;35:98-100. [PMID: 8307460 DOI: 10.1136/gut.35.1.98] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
187 Ikeguchi M, Saito H, Katano K, Tsujitani S, Maeta M, Kaibara N. Expression of p53 and p21 are independent prognostic factors in patients with serosal invasion by gastric carcinoma. Dig Dis Sci 1998;43:964-70. [PMID: 9590408 DOI: 10.1023/a:1018862214081] [Cited by in Crossref: 23] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
188 Cordone I, Masi S, Mauro FR, Soddu S, Morsilli O, Valentini T, Vegna ML, Guglielmi C, Mancini F, Giuliacci S, Sacchi A, Mandelli F, Foa R. p53 Expression in B-Cell Chronic Lymphocytic Leukemia: A Marker of Disease Progression and Poor Prognosis. Blood 1998;91:4342-9. [DOI: 10.1182/blood.v91.11.4342] [Cited by in Crossref: 144] [Article Influence: 6.3] [Reference Citation Analysis]
189 Sgambato A, Migaldi M, Leocata P, Ventura L, Criscuolo M, Di Giacomo C, Capelli G, Cittadini A, De Gaetani C. Loss of p27Kip1 expression is a strong independent prognostic factor of reduced survival in N0 gastric carcinomas. Cancer 2000;89:2247-57. [DOI: 10.1002/1097-0142(20001201)89:11<2247::aid-cncr13>3.0.co;2-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
190 Dowell SP, Hall PA. The clinical relevance of the p53 tumour suppressor gene. Cytopathology 1994;5:133-45. [PMID: 7919056 DOI: 10.1111/j.1365-2303.1994.tb00409.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
191 Joypaul BV, Vojtesek B, Newman EL, Hopwood D, Grant A, Lane DP, Cuschieri A. Enzyme-linked immunosorbent assay for p53 in gastrointestinal malignancy: comparison with immunohistochemistry. Histopathology 1993;23:465-70. [DOI: 10.1111/j.1365-2559.1993.tb00496.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
192 Jonas S, Springmeier G, Tauber R, Wiedenmann B, Lobeck H, Gessner R, Kreft B, Kling N, Moelling K, Neuhaus P. p53 mutagenesis in klatskin tumors. Human Pathology 1998;29:955-60. [DOI: 10.1016/s0046-8177(98)90200-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
193 Roviello F, Marrelli D, Vindigni C, De Stefano A, Spina D, Pinto E. p53 Accumulation Is a Prognostic Factor in Intestinal-Type Gastric Carcinoma but Not in the Diffuse Type. Ann Surg Oncol 1999;6:739-45. [DOI: 10.1007/s10434-999-0739-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
194 Aizawa S, Sasaki M, Wada R, Koyama M, Yagihashi S. P53 protein expression in pancreatic tumors and its relationship to clinicopathological factors and prognosis. J Surg Oncol 1996;62:279-83. [PMID: 8691842 DOI: 10.1002/(SICI)1096-9098(199608)62:4<279::AID-JSO11>3.0.CO;2-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
195 Shimaya K, Shiozaki H, Inoue M, Tahara H, Monden T, Shimano T, Mori T. Significance of p53 expression as a prognostic factor in oesophageal squamous cell carcinoma. Vichows Archiv A Pathol Anat 1993;422:271-6. [DOI: 10.1007/bf01608335] [Cited by in Crossref: 61] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
196 Goldstone AR, Quirke P, Dixon MF. Helicobacter pylori infection and gastric cancer. J Pathol 1996;179:129-37. [PMID: 8758203 DOI: 10.1002/(SICI)1096-9896(199606)179:2<129::AID-PATH504>3.0.CO;2-C] [Cited by in Crossref: 30] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
197 Nagao T, Kondo F, Sato T, Nagato Y, Kondo Y. Immunohistochemical detection of aberrant p53 expression in hepatocellular carcinoma: correlation with cell proliferative activity indices, including mitotic index and MIB-1 immunostaining. Hum Pathol. 1995;26:326-333. [PMID: 7890286 DOI: 10.1016/0046-8177(95)90066-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 1.2] [Reference Citation Analysis]
198 Vojtesek B, Lane D. Regulation of p53 protein expression in human breast cancer cell lines. Journal of Cell Science 1993;105:607-12. [DOI: 10.1242/jcs.105.3.607] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 1.4] [Reference Citation Analysis]
199 Diamandis EP. Clinical applications of tumor suppressor genes and oncogenes in cancer. Clinica Chimica Acta 1997;257:157-80. [DOI: 10.1016/s0009-8981(96)06442-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
200 Ajith TA, Soja M. A comparative study on the antimutagenicity of atorvastatin and lovastatin against directly acting mutagens. Cell Biol Toxicol 2006;22:269-74. [DOI: 10.1007/s10565-006-0064-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
201 Mo P, Xie S, Cai W, Ruan J, Du Q, Ye J, Mao J. N6-methyladenosine (m6A) RNA methylation signature as a predictor of stomach adenocarcinoma outcomes and its association with immune checkpoint molecules. J Int Med Res 2020;48:300060520951405. [PMID: 32972288 DOI: 10.1177/0300060520951405] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
202 Nakopoulou L, Constantinides C, Papandropoulos J, Theodoropoulos G, Tzonou A, Giannopoulos A, Zervas A, Dimopoulos C. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: Comparison with dna ploidy. Urology 1995;46:334-40. [DOI: 10.1016/s0090-4295(99)80216-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
203 Kawamura A, Adachi K, Ishihara S, Katsube T, Takashima T, Yuki M, Amano K, Fukuda R, Yamashita Y, Kinoshita Y. Correlation between microsatellite instability and metachronous disease recurrence after endoscopic mucosal resection in patients with early stage gastric carcinoma. Cancer 2001;91:339-45. [DOI: 10.1002/1097-0142(20010115)91:2<339::aid-cncr1007>3.0.co;2-2] [Cited by in Crossref: 11] [Article Influence: 0.6] [Reference Citation Analysis]
204 Diamandis EP. Clinical applications of the p53 tumor suppressor gene. Clinica Chimica Acta 1995;237:79-90. [DOI: 10.1016/0009-8981(95)06066-m] [Cited by in Crossref: 9] [Article Influence: 0.3] [Reference Citation Analysis]
205 Amadori D, Maltoni M, Volpi A, Nanni O, Scarpi E, Renault B, Pellegata NS, Gaudio M, Magni E, Ranzani GN. Gene amplification and proliferative kinetics in relation to prognosis of patients with gastric carcinoma. Cancer 1997;79:226-32. [DOI: 10.1002/(sici)1097-0142(19970115)79:2<226::aid-cncr5>3.0.co;2-i] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
206 Xia Y, Li X, Sun W. Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China. Curr Gene Ther 2020;20:127-41. [PMID: 32951572 DOI: 10.2174/1566523220999200731003206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
207 Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. Multifactorial analysis ofp53 alteration in human cancer: A review. Int J Cancer 1994;57:1-9. [DOI: 10.1002/ijc.2910570102] [Cited by in Crossref: 230] [Cited by in F6Publishing: 204] [Article Influence: 8.5] [Reference Citation Analysis]
208 Donehower LA, Bradley A. The tumor suppressor p53. Biochim Biophys Acta 1993;1155:181-205. [PMID: 8357826 DOI: 10.1016/0304-419x(93)90004-v] [Cited by in Crossref: 23] [Cited by in F6Publishing: 59] [Article Influence: 0.8] [Reference Citation Analysis]